Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Sacituzumab Tirumotecan in combination with Tagitanlimab for aggressive variant and neuroendocrine prostate cancers; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma with Neuroendocrine Differentiation
• Prostate Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)
• Tagitanlimab

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant | Phase 2 | Status: RECRUITING